Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06817395 · ClinicalTrials.gov registry record
Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
A clinical trial of Immune Thrombocytopenia, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06817395: Recruiting study of Immune Thrombocytopenia, sponsored by Massachusetts General Hospital.
NCT06817395 is a study of Immune Thrombocytopenia that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, roughly in line with the 107-participant average among 6 other Immune Thrombocytopenia trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06817395, a study of Immune Thrombocytopenia, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Individuals with immune thrombocytopenia (ITP) frequently report difficulties with attention and memory. The main question this study seeks to answer is: Do patients with ITP have evidence of cognitive impairment as detected by a cognitive function test battery? To address this issue, participants will take a cognitive function test and complete surveys on quality of life, fatigue, depression, and cognitive symptoms. The primary aim of the study is to evaluate for the presence and extent of cognitive impairment in patients with ITP. The study will also assess whether cognitive impairment in ITP is associated with patient-reported impacts on quality of life, fatigue, mood, and cognitive symptoms as well as clinical characteristics such as ITP disease and treatment history.
Primary Outcome
Proportion of subjects with mild (T-score 1 to 2 standard deviations \[SDs\] below the normative mean) or major (\>2 SDs below the normative mean) impairment of the composite measure of fluid cognition, as detected on the NIH Toolbox cognition battery.
Conditions Studied
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-09-15 |
| Est. Completion | 2028-09-15 |
What NCT06817395 shows while recruiting
NCT06817395 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 107-participant average among 6 other Immune Thrombocytopenia trials with a reported enrollment target.
The record links to 1 condition, with Immune Thrombocytopenia appearing as the primary indexed condition, and to 0 interventions.
NCT06817395 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06817395 about?
NCT06817395 is a clinical study titled "Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia". Individuals with immune thrombocytopenia (ITP) frequently report difficulties with attention and memory. The main question this study seeks to answer is: Do patients with ITP have evidence of cognitive impairment as detected by a cognitive function test battery? To address this issue, participants...
What is the current status of trial NCT06817395?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-09-15. Estimated completion is 2028-09-15.
What conditions does trial NCT06817395 study?
This clinical trial studies the following conditions: Immune Thrombocytopenia.
Who is sponsoring clinical trial NCT06817395?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06817395 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
RECRUITING · Phase 3
-
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
COMPLETED · Phase 4
-
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI